Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Jardiance (empagliflozin) and Glyburide are both medications used to manage Type 2 diabetes, but they work in different ways and have distinct characteristics. Jardiance is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that helps lower blood sugar by causing your body to excrete excess sugar through urine. It also has benefits for heart failure and chronic kidney disease. Glyburide, on the other hand, is a sulfonylurea that lowers blood sugar by prompting your pancreas to release more insulin. Jardiance is taken once daily and is currently only available as a brand-name medication, with generics expected after 2025. Glyburide can be taken once or twice daily and is available in both generic and micronized forms. While Jardiance can cause urinary tract and yeast infections, Glyburide has a higher risk of causing low blood sugar and weight gain. Additionally, Jardiance is not recommended during the later stages of pregnancy, whereas glyburide's safety during pregnancy is not well-studied.
Glyburide is taken by mouth to lower blood sugar levels for people who have Type 2 diabetes. This medication isn't meant to be taken alone, but in addition to eating a healthy diet and engaging in regular exercise. Glyburide is typically taken once or twice daily, depending on your dose.
Indications of Jardiance vs. Glyburide
Indications for
•Type 2 diabetes (in addition to diet and exercise) in people age 10 years and older
•Lowering the risk of death due to heart problems in adults with Type 2 diabetes and heart disease
•Lowering the risk of hospitalization and death due to heart problems in adults with heart failure
•Lowering the risk of worsening kidney problems, hospitalization, and death due to heart problems in adults with chronic kidney disease (CKD)